Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study Meeting Abstract
| Authors: | Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; Perini, R. F.; McKenzie, J.; Mody, K.; Motzer, R. J. |
| Abstract Title: | Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301335 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.4514 |
| Notes: | Meeting Abstract: 4514 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
